MeiraGTx Holdings plc Stock-Based Compensation
MeiraGTx Holdings plc (MGTX) reported Stock-Based Compensation of $7.43 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-13
- MeiraGTx Holdings plc share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $3.78M, a 33.22% decline year-over-year.
- MeiraGTx Holdings plc share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $3.65M, a 25.23% decline year-over-year.
- MeiraGTx Holdings plc share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $5.60M, a 8.44% decline year-over-year.
- MeiraGTx Holdings plc share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $5.95M, a 5.58% decline year-over-year.
- MeiraGTx Holdings plc share-based payment arrangement, noncash expense for fiscal 2025 was $22.11M, a 12.25% decline from fiscal 2024.
- MeiraGTx Holdings plc share-based payment arrangement, noncash expense for fiscal 2024 was $25.19M, a 9.11% decline from fiscal 2023.
- MeiraGTx Holdings plc share-based payment arrangement, noncash expense for fiscal 2023 was $27.72M, a 3.17% decline from fiscal 2022.
- MeiraGTx Holdings plc share-based payment arrangement, noncash expense for fiscal 2022 was $28.62M, a 37.72% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 6 month as first filed | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 9 month as first filed | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $7.43M 10-Q · filed 2026-08-13 | $13.03M derived: sum of 3 quarters · filed 2026-08-13 | $18.99M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $3.65M 10-Q · filed 2026-05-14 | $9.26M derived: sum of 2 quarters · filed 2026-05-14 | $15.21M derived: sum of 3 quarters · filed 2026-05-14 | $20.87M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2025-12-31 | $5.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $11.55M derived: sum of 2 quarters · filed 2026-03-30 | $17.21M derived: sum of 3 quarters · filed 2026-03-30 | $22.11M 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | $5.95M 10-Q · filed 2025-11-13 | $11.61M derived: sum of 2 quarters · filed 2025-11-13 | $16.50M 10-Q · filed 2025-11-13 | $22.61M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2025-06-30 | $5.66M 10-Q · filed 2025-08-14 | $10.55M 10-Q · filed 2026-08-13 | $16.66M derived: sum of 3 quarters · filed 2026-05-14 | $22.97M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2025-03-31 | $4.89M 10-Q · filed 2026-05-14 | $11.00M derived: sum of 2 quarters · filed 2026-05-14 | $17.31M derived: sum of 3 quarters · filed 2026-05-14 | $23.11M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | $6.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $12.42M derived: sum of 2 quarters · filed 2026-03-30 | $18.23M derived: sum of 3 quarters · filed 2026-03-30 | $25.19M 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | $6.30M 10-Q · filed 2025-11-13 | $12.11M derived: sum of 2 quarters · filed 2025-11-13 | $19.07M 10-Q · filed 2025-11-13 | $26.03M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $5.81M 10-Q · filed 2025-08-14 | $12.77M 10-Q · filed 2025-08-14 | $19.73M derived: sum of 3 quarters · filed 2025-08-14 | $26.78M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | $6.96M 10-Q · filed 2025-05-13 | $13.92M derived: sum of 2 quarters · filed 2025-05-13 | $20.97M derived: sum of 3 quarters · filed 2025-05-13 | $28.24M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | $6.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $14.01M derived: sum of 2 quarters · filed 2025-03-13 | $21.28M derived: sum of 3 quarters · filed 2025-03-13 | $27.72M 10-K · filed 2025-03-13 | ||||
| 2023-09-30 | $7.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $14.32M derived: sum of 2 quarters · filed 2024-11-13 | $20.76M 10-Q · filed 2024-11-13 | $27.56M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $7.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $13.70M 10-Q · filed 2024-08-12 | $20.51M derived: sum of 3 quarters · filed 2024-08-12 | $27.45M derived: sum of 4 quarters · filed 2024-08-12 | ||||
| 2023-03-31 | $6.43M 10-Q · filed 2024-05-09 | $13.24M derived: sum of 2 quarters · filed 2024-05-09 | $20.17M derived: sum of 3 quarters · filed 2024-05-09 | $27.48M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $6.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $13.74M derived: sum of 2 quarters · filed 2024-03-15 | $21.05M derived: sum of 3 quarters · filed 2024-03-15 | $28.62M 10-K · filed 2024-03-15 | ||||
| 2022-09-30 | $6.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $14.24M derived: sum of 2 quarters · filed 2023-11-14 | $21.82M 10-Q · filed 2023-11-14 | $27.24M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | $7.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $14.88M 10-Q · filed 2023-08-10 | $20.31M derived: sum of 3 quarters · filed 2023-08-10 | $25.64M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $7.58M 10-Q · filed 2023-05-11 | $13.00M derived: sum of 2 quarters · filed 2023-05-11 | $18.34M derived: sum of 3 quarters · filed 2023-05-11 | $23.55M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $5.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $10.76M derived: sum of 2 quarters · filed 2023-03-14 | $15.97M derived: sum of 3 quarters · filed 2023-03-14 | $20.78M 10-K · filed 2023-03-14 | ||||
| 2021-09-30 | $5.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $10.54M derived: sum of 2 quarters · filed 2022-11-10 | $15.36M 10-Q · filed 2022-11-10 | $19.30M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | $5.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $10.02M 10-Q · filed 2022-08-11 | $13.96M derived: sum of 3 quarters · filed 2022-08-11 | $17.70M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $4.82M 10-Q · filed 2022-05-12 | $8.76M derived: sum of 2 quarters · filed 2022-05-12 | $12.49M derived: sum of 3 quarters · filed 2022-05-12 | $17.55M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $3.94M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $7.68M derived: sum of 2 quarters · filed 2022-03-10 | $12.73M derived: sum of 3 quarters · filed 2022-03-10 | $18.42M 10-K · filed 2022-03-10 | $18.42M 10-K · filed 2021-03-11 | |||
| 2020-09-30 | $3.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $8.79M derived: sum of 2 quarters · filed 2021-11-10 | $14.48M 10-Q · filed 2021-11-10 | $14.48M 10-Q · filed 2020-11-05 | $19.58M derived: sum of 4 quarters · filed 2021-11-10 | |||
| 2020-06-30 | $5.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $10.74M 10-Q · filed 2021-08-11 | $10.74M 10-Q · filed 2020-08-06 | $15.84M derived: sum of 3 quarters · filed 2021-08-11 | $19.35M derived: sum of 4 quarters · filed 2021-08-11 | |||
| 2020-03-31 | $5.68M 10-Q · filed 2021-05-11 | $5.68M 10-Q · filed 2020-05-07 | $10.79M derived: sum of 2 quarters · filed 2021-05-11 | $14.29M derived: sum of 3 quarters · filed 2021-05-11 | $18.68M derived: sum of 4 quarters · filed 2021-05-11 | |||
| 2019-12-31 | $5.10M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $8.61M derived: sum of 2 quarters · filed 2021-03-11 | $12.99M derived: sum of 3 quarters · filed 2021-03-11 | $15.93M 10-K · filed 2021-03-11 | ||||
| 2019-09-30 | $3.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $7.89M derived: sum of 2 quarters · filed 2020-11-05 | $10.83M 10-Q · filed 2020-11-05 | $13.15M derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2019-06-30 | $4.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $7.32M 10-Q · filed 2020-08-06 | $9.65M derived: sum of 3 quarters · filed 2020-08-06 | $12.57M derived: sum of 4 quarters · filed 2020-08-06 | ||||
| 2019-03-31 | $2.93M 10-Q · filed 2020-05-07 | $5.26M derived: sum of 2 quarters · filed 2020-05-07 | $8.18M derived: sum of 3 quarters · filed 2020-05-07 | $16.54M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2018-12-31 | $2.33M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $5.25M derived: sum of 2 quarters · filed 2020-03-11 | $13.61M derived: sum of 3 quarters · filed 2020-03-11 | $17.88M 10-K · filed 2020-03-11 | ||||
| 2018-09-30 | $2.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $11.28M derived: sum of 2 quarters · filed 2019-11-07 | $15.56M 10-Q · filed 2019-11-07 | $16.50M derived: sum of 4 quarters · filed 2019-11-07 | ||||
| 2018-06-30 | $8.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $12.63M 10-Q · filed 2019-08-07 | $13.57M derived: sum of 3 quarters · filed 2019-08-07 | $14.06M derived: sum of 4 quarters · filed 2019-08-07 | ||||
| 2018-03-31 | $4.28M 10-Q · filed 2019-05-14 | $5.22M derived: sum of 2 quarters · filed 2019-05-14 | $5.70M derived: sum of 3 quarters · filed 2019-05-14 | |||||
| 2017-12-31 | $940.08K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $1.42M derived: sum of 2 quarters · filed 2019-03-26 | $2.96M 10-K · filed 2019-03-26 | |||||
| 2017-09-30 | $484.56K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $2.02M 10-Q · filed 2018-11-08 | ||||||
| 2017-06-30 | $1.54M 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |